王杰军:肿瘤姑息治疗应贯穿癌症治疗的全过程

2016-06-17 MedSci MedSci原创

为了交流国内外临床肿瘤姑息治疗领域的实践经验和科研成果,积极推动我国姑息治疗学科的健康迅速发展,由中国抗癌协会癌症康复与姑息治疗专业委员会(CRPC)主办,CSCO、《临床肿瘤学杂志》社和安徽医科大学第一附属医院协办的第十二届全国癌症康复与姑息医学大会,于2016年6月17日~19日在合肥举行。 本届大会的主题是“科学、人文、实践、合作”。梅斯医学作为媒体合作单位采访了大会主席王杰军教授

为了交流国内外临床肿瘤姑息治疗领域的实践经验和科研成果,积极推动我国姑息治疗学科的健康迅速发展,由中国抗癌协会癌症康复与姑息治疗专业委员会(CRPC)主办,CSCO、《临床肿瘤学杂志》社和安徽医科大学第一附属医院协办的第十二届全国癌症康复与姑息医学大会,于2016年6月17日~19日在合肥举行。

本届大会的主题是“科学、人文、实践、合作”。梅斯医学作为媒体合作单位采访了大会主席王杰军教授,以下为现场报告。

癌症姑息治疗的概念——并非局限于癌症晚期

王杰军教授指出,世界姑息治疗联盟WPCA在2014年的最新统计显示,在姑息治疗理念接受程度上中国处于全世界领先地位,而姑息治疗的设施及实施上却远远落后于世界平均水平。

癌症的姑息治疗并非是指癌症晚期的治疗,国际上将其定位为肿瘤标准治疗的一部分。世界卫生组织对姑息治疗的定义是指:对那些对治愈性治疗不反应的病人完全的主动的治疗和护理。对不可自愈性疾病采取的所有治疗措施都属于姑息性治疗。目前绝大部分恶性肿瘤属于不可自愈性疾病,因此对恶性肿瘤的所有治疗应属于姑息治疗的范畴。其目的是为病人和家属赢得最好的生活质量。应强调症状控制、患者支持、提升生活质量等多方面的内涵,包括症状的控制、营养,心理,社会等各个方面。

国内一直存在姑息治疗的理念,但没有得到规范化的实施。我们首先从肿瘤疼痛的规范化治疗做起。CRPC联合国家卫生部和卫计委举办了中国癌痛规范示范病房项目,在全国范围内已经有700多家医院通过验收。这个项目在亚太地区已经产生了重大的影响。除了概念的普及之外,也非常注重医生的规范治疗教育,在2015年成立了中国肿瘤姑息治疗临床学院CPAC项目,包括疼痛学院、营养学院、骨健康学院、社工学院,关注癌症治疗最重要的方面。

最初在1998年,美国临床肿瘤学会(ASCO)提出:肿瘤专家以及姑息团队的职责不仅仅在于治疗癌症,而是应该将姑息治疗与标准抗肿瘤治疗贯穿疾病治疗全过程。

姑息治疗对肿瘤患者的获益不只是减轻痛苦

王杰军教授指出,在国内传统传统概念认为肿瘤姑息治疗是晚期肿瘤患者的缓解治疗,但姑息治疗对肿瘤患者的获益不只是减轻痛苦,更有实质性的获益。

2010年,《新英格兰杂志》曾发表了一项研究,麻省理工医院针对151名非小细胞肺癌患者,化疗+姑息治疗的联合治疗组比单纯化疗组的生存期延长了2.7个月,且病人对治疗的满意度明显升高。这个结果告诉人们姑息治疗不只是减轻痛苦,保证生活质量,也起到了延长生命的实质性作用。(NEJM:早期姑息疗法治疗转移性非小细胞肺癌患者)

2014年发表在JCO的文章显示:姑息治疗越早,节省越多。研究人员收集了美国5家医院的晚期癌症患者的临床和开支数据,样本共包含了969例晚期癌症患者;256人接受姑息治疗咨询团队的照看,其余713人只接受常规的治疗方案。研究结果显示在住院后,更早的进行姑息治疗咨询可以减少罹患晚期癌症的病人的住院开支。(JCO:姑息治疗越早,节省越多 )

2014美国临床肿瘤学会(ASCO)年会所发布的ENABLE III研究中,来自美国阿拉巴马大学伯明翰分校综合癌症中心等机构的研究者探讨了晚期癌症姑息治疗启动时间对照料者的影响。12周之前,姑息治疗即刻组照料者的抑郁及SB水平更低,QOL更高。结果提示,肿瘤姑息治疗应越早越好,以最大程度地为患者带来获益。ASCO 2014:晚期癌症姑息治疗 越早越好( ENABLE III研究))

ASCO大会专家,加州大学洛杉矶分校(UCLA)医学与公共卫生学院 PatriciaGanz医生点评: “本项创新性研究体现了为癌症照料者提供支持的需要,以及’赶早不赶晚’所带来的获益。改善照料者的精神健康及舒适度也是姑息治疗的重要组成部分。”

肿瘤姑息治疗在临床实践中的具体应用策略

对患者的治疗前评估,除了肿瘤本身的评估,还应对患者的症状,感受进行评估。

目前在国内,肿瘤科医生肩负了营养科、心理科医生的责任,缺乏专业性,各个科室会诊会增加患者治疗的复杂性和困难性。最近我们向国家卫计委提出了新的建议,希望在中国建立肿瘤姑息治疗科。在三级医院成立亚学科,即肿瘤治疗团队及肿瘤姑息治疗团队,由两个亚学科团队进行全院会诊。这是目前国际上共同采取的模式,这种整合的模式使得患者在治疗肿瘤的同时,得到症状和体能的评价。中国肿瘤姑息治疗临床学院已经培养了上百名国外进修的高级别肿瘤科医生,通过线上线下的继续教育学习,希望对肿瘤患者进行系统,综合的治疗,真正为患者谋福祉。

总结:

肿瘤的姑息治疗≠临终关怀,肿瘤的姑息治疗宜早不宜晚,临床医生应更加系统、全面、客观、科学的进行姑息治疗,让中国肿瘤患者和家属都能拥有更好的生存质量。

专家介绍:


王杰军,教授,医学博士,博士研究生导师,毕业于第二军医大学,现任长征医院肿瘤科主任。中国人民解放军肿瘤专业委员会主任委员、中华医学会上海分会肿瘤专科委员会前任主任委员、中国生命关怀协会副会长、上海癌症康复与姑息治疗专业委员会主任委员、中国癌症康复与姑息治疗专业委员会候任主任委员、上海市防癌抗癌事业发展基金会副理事长、中国临床肿瘤协作中心(CSCO)常务委员、中华医学会疼痛学分会常务委员、国家药品监督管理局药物审评委员会委员、解放军肿瘤研究所副所长、上海综合性医院肿瘤防治专业委员会主任委员等。

梅斯医学

梅斯医学(MedSci)是中国领先的医生互联网平台,拥有超过120万注册医生用户,主要从事临床研究、医生继续教育和培训,以及智慧医疗服务,旨在推动和加速临床医生的职业成长,改善医疗质量。

更多全国癌症康复与姑息医学大会内容,请关注梅斯医学APP


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2009395, encodeId=b5a5200939522, content=<a href='/topic/show?id=51b429e159a' target=_blank style='color:#2F92EE;'>#全过程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29715, encryptionId=51b429e159a, topicName=全过程)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Nov 29 00:09:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034253, encodeId=33f920342530d, content=<a href='/topic/show?id=1fe6828956d' target=_blank style='color:#2F92EE;'>#肿瘤姑息治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82895, encryptionId=1fe6828956d, topicName=肿瘤姑息治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Thu May 11 06:09:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027228, encodeId=190e202e228ae, content=<a href='/topic/show?id=e99a6832044' target=_blank style='color:#2F92EE;'>#王杰军#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68320, encryptionId=e99a6832044, topicName=王杰军)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Sun Jul 10 19:09:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844184, encodeId=dba21844184e5, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Nov 02 14:09:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626625, encodeId=12ac1626625b8, content=<a href='/topic/show?id=2d91449540c' target=_blank style='color:#2F92EE;'>#姑息#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44954, encryptionId=2d91449540c, topicName=姑息)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adea21051784, createdName=经常头晕, createdTime=Sun Jun 19 14:09:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90357, encodeId=da009035e28, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 18:00:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90319, encodeId=288c90319cb, content=观念很好,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sat Jun 18 09:46:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2009395, encodeId=b5a5200939522, content=<a href='/topic/show?id=51b429e159a' target=_blank style='color:#2F92EE;'>#全过程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29715, encryptionId=51b429e159a, topicName=全过程)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Nov 29 00:09:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034253, encodeId=33f920342530d, content=<a href='/topic/show?id=1fe6828956d' target=_blank style='color:#2F92EE;'>#肿瘤姑息治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82895, encryptionId=1fe6828956d, topicName=肿瘤姑息治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Thu May 11 06:09:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027228, encodeId=190e202e228ae, content=<a href='/topic/show?id=e99a6832044' target=_blank style='color:#2F92EE;'>#王杰军#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68320, encryptionId=e99a6832044, topicName=王杰军)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Sun Jul 10 19:09:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844184, encodeId=dba21844184e5, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Nov 02 14:09:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626625, encodeId=12ac1626625b8, content=<a href='/topic/show?id=2d91449540c' target=_blank style='color:#2F92EE;'>#姑息#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44954, encryptionId=2d91449540c, topicName=姑息)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adea21051784, createdName=经常头晕, createdTime=Sun Jun 19 14:09:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90357, encodeId=da009035e28, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 18:00:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90319, encodeId=288c90319cb, content=观念很好,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sat Jun 18 09:46:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2009395, encodeId=b5a5200939522, content=<a href='/topic/show?id=51b429e159a' target=_blank style='color:#2F92EE;'>#全过程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29715, encryptionId=51b429e159a, topicName=全过程)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Nov 29 00:09:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034253, encodeId=33f920342530d, content=<a href='/topic/show?id=1fe6828956d' target=_blank style='color:#2F92EE;'>#肿瘤姑息治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82895, encryptionId=1fe6828956d, topicName=肿瘤姑息治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Thu May 11 06:09:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027228, encodeId=190e202e228ae, content=<a href='/topic/show?id=e99a6832044' target=_blank style='color:#2F92EE;'>#王杰军#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68320, encryptionId=e99a6832044, topicName=王杰军)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Sun Jul 10 19:09:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844184, encodeId=dba21844184e5, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Nov 02 14:09:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626625, encodeId=12ac1626625b8, content=<a href='/topic/show?id=2d91449540c' target=_blank style='color:#2F92EE;'>#姑息#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44954, encryptionId=2d91449540c, topicName=姑息)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adea21051784, createdName=经常头晕, createdTime=Sun Jun 19 14:09:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90357, encodeId=da009035e28, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 18:00:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90319, encodeId=288c90319cb, content=观念很好,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sat Jun 18 09:46:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2009395, encodeId=b5a5200939522, content=<a href='/topic/show?id=51b429e159a' target=_blank style='color:#2F92EE;'>#全过程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29715, encryptionId=51b429e159a, topicName=全过程)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Nov 29 00:09:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034253, encodeId=33f920342530d, content=<a href='/topic/show?id=1fe6828956d' target=_blank style='color:#2F92EE;'>#肿瘤姑息治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82895, encryptionId=1fe6828956d, topicName=肿瘤姑息治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Thu May 11 06:09:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027228, encodeId=190e202e228ae, content=<a href='/topic/show?id=e99a6832044' target=_blank style='color:#2F92EE;'>#王杰军#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68320, encryptionId=e99a6832044, topicName=王杰军)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Sun Jul 10 19:09:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844184, encodeId=dba21844184e5, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Nov 02 14:09:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626625, encodeId=12ac1626625b8, content=<a href='/topic/show?id=2d91449540c' target=_blank style='color:#2F92EE;'>#姑息#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44954, encryptionId=2d91449540c, topicName=姑息)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adea21051784, createdName=经常头晕, createdTime=Sun Jun 19 14:09:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90357, encodeId=da009035e28, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 18:00:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90319, encodeId=288c90319cb, content=观念很好,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sat Jun 18 09:46:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2009395, encodeId=b5a5200939522, content=<a href='/topic/show?id=51b429e159a' target=_blank style='color:#2F92EE;'>#全过程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29715, encryptionId=51b429e159a, topicName=全过程)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Nov 29 00:09:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034253, encodeId=33f920342530d, content=<a href='/topic/show?id=1fe6828956d' target=_blank style='color:#2F92EE;'>#肿瘤姑息治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82895, encryptionId=1fe6828956d, topicName=肿瘤姑息治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Thu May 11 06:09:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027228, encodeId=190e202e228ae, content=<a href='/topic/show?id=e99a6832044' target=_blank style='color:#2F92EE;'>#王杰军#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68320, encryptionId=e99a6832044, topicName=王杰军)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Sun Jul 10 19:09:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844184, encodeId=dba21844184e5, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Nov 02 14:09:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626625, encodeId=12ac1626625b8, content=<a href='/topic/show?id=2d91449540c' target=_blank style='color:#2F92EE;'>#姑息#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44954, encryptionId=2d91449540c, topicName=姑息)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adea21051784, createdName=经常头晕, createdTime=Sun Jun 19 14:09:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90357, encodeId=da009035e28, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 18:00:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90319, encodeId=288c90319cb, content=观念很好,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sat Jun 18 09:46:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2009395, encodeId=b5a5200939522, content=<a href='/topic/show?id=51b429e159a' target=_blank style='color:#2F92EE;'>#全过程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29715, encryptionId=51b429e159a, topicName=全过程)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Nov 29 00:09:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034253, encodeId=33f920342530d, content=<a href='/topic/show?id=1fe6828956d' target=_blank style='color:#2F92EE;'>#肿瘤姑息治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82895, encryptionId=1fe6828956d, topicName=肿瘤姑息治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Thu May 11 06:09:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027228, encodeId=190e202e228ae, content=<a href='/topic/show?id=e99a6832044' target=_blank style='color:#2F92EE;'>#王杰军#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68320, encryptionId=e99a6832044, topicName=王杰军)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Sun Jul 10 19:09:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844184, encodeId=dba21844184e5, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Nov 02 14:09:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626625, encodeId=12ac1626625b8, content=<a href='/topic/show?id=2d91449540c' target=_blank style='color:#2F92EE;'>#姑息#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44954, encryptionId=2d91449540c, topicName=姑息)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adea21051784, createdName=经常头晕, createdTime=Sun Jun 19 14:09:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90357, encodeId=da009035e28, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 18:00:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90319, encodeId=288c90319cb, content=观念很好,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sat Jun 18 09:46:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
    2016-06-18 沉心多思

    好文章,值得学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2009395, encodeId=b5a5200939522, content=<a href='/topic/show?id=51b429e159a' target=_blank style='color:#2F92EE;'>#全过程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29715, encryptionId=51b429e159a, topicName=全过程)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Nov 29 00:09:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034253, encodeId=33f920342530d, content=<a href='/topic/show?id=1fe6828956d' target=_blank style='color:#2F92EE;'>#肿瘤姑息治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82895, encryptionId=1fe6828956d, topicName=肿瘤姑息治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Thu May 11 06:09:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027228, encodeId=190e202e228ae, content=<a href='/topic/show?id=e99a6832044' target=_blank style='color:#2F92EE;'>#王杰军#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68320, encryptionId=e99a6832044, topicName=王杰军)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f378286, createdName=shalley66, createdTime=Sun Jul 10 19:09:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844184, encodeId=dba21844184e5, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Nov 02 14:09:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626625, encodeId=12ac1626625b8, content=<a href='/topic/show?id=2d91449540c' target=_blank style='color:#2F92EE;'>#姑息#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44954, encryptionId=2d91449540c, topicName=姑息)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adea21051784, createdName=经常头晕, createdTime=Sun Jun 19 14:09:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90357, encodeId=da009035e28, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 18:00:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90319, encodeId=288c90319cb, content=观念很好,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sat Jun 18 09:46:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
    2016-06-18 huangwukui

    观念很好,值得学习

    0

相关资讯

王杰军:奋进中的中国肿瘤姑息治疗 ——CRPC中国行癌痛专场郑州站

2016年4月16日,由中国抗癌协会癌症康复与姑息治疗专业委员会(CRPC)主办,羚锐公司承办的CRPC中国行癌痛专场在郑州承办召开,与会的是来自河南、河北、北京等地区的肿瘤治疗专家120多人。 大会主席由CRPC主任委员,上海长征医院的王杰军教授与CRPC常务委员,河南省肿瘤医院罗素霞教授共同担任。 本次会议的前一天正值中国抗癌协会发起的4.15全